Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Adjuvant Chemotherapy Plus Apatinib in Gastric Cancer
ChiCTR-IPR-16008335Phase 4Not yet recruiting
- Sponsor
- 904th Hospital of the Joint Logistic Support Force
- Start
- Apr 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Rivoceranib in gastric cancer (GC) (2 arms), sponsored by 904th Hospital of the Joint Logistic Support Force. Primary endpoint: Progression-free survival. Planned start Apr 2016; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-IPR-16008335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008335.